Indexed In : Science Citation Index Expanded(SCIE), MEDLINE,
Pubmed/Pubmed Central, Elsevier Bibliographic, Google Scholar,
Databases(Scopus & Embase), KCI, KoreaMed, DOAJ
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Chan Sik Won*, Mee Yon Cho†, Hyun Soo Kim**, Hye Jeong Kim*, Ki Tae Suk‡, Moon Young Kim*, Jae Woo Kim*, Soon Koo Baik*, and Sang Ok Kwon*
*Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
†Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea.
‡Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.
Correspondence to: Hyun Soo Kim. Department of Internal Medicine, Yonsei University Wonju College of Medicine, 162 Ilsan-dong, Wonju 220-701, Korea. Tel: +82-33-741-1229, Fax: +82-33-745-6782, hyskim@yonsei.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2011;5(2):187-193. https://doi.org/10.5009/gnl.2011.5.2.187
Published online June 23, 2011, Published date June 30, 2011
Copyright © Gut and Liver.
Gastric dysplasia is generally accepted to be the precursor lesion of gastric carcinoma. Approximately 25% to 35% of histological diagnoses based on endoscopic forcep biopsies for gastric dysplastic lesions change following endoscopic resection (ER). The aim of this study was to determine the predictive endoscopic features of high-grade gastric dysplasia (HGD) or early gastric cancer (EGC) following ER for lesions initially diagnosed as low-grade dysplasia (LGD) by a forceps biopsy.
To determine predictive variables for upgraded histology (LGD to HGD or EGC). The lesion size, gross endoscopic appearance, location, and surface nodularity or redness as well as the presence of a depressed portion,
Among 251 LGDs diagnosed by an initial forceps biopsy, the diagnoses of 100 lesions (39.8%) changed following the ER; 56 of 251 LGDs (22.3%) were diagnosed as HGD, 39 (15.5%) as adenocarcinoma, and 5 (2.0%) as chronic gastritis. In a univariate analysis, large lesions (>15 mm), those with a depressed portion, and those with surface nodularity were significantly correlated with a upgraded histology classification following ER. In a multivariate analysis, a large size (>15 mm; odds ratio [OR], 2.8; 95% confidence interval [CI], 1.46 to 5.43) and a depressed portion in the lesion (OR, 2.7; 95% CI, 1.44 to 5.03) were predictive factors for upgraded histology following ER.
Our study shows that a substantial proportion of diagnoses of low-grade gastric dysplasias based on forceps biopsies were not representative of the entire lesion. We recommend ER for lesions with a depressed portion and for those larger than 15 mm.
Keywords: Gastric dysplasia, Endoscopic forcep biopsy, Endoscopic resection, Early gastric cancer
Dysplasia refers to an unequivocal neoplastic transformation in the epithelium without penetration into the lamina propria (intramucosal carcinoma).1,2 Gastric dysplasia is generally accepted to be a precursor lesion for gastric carcinoma.3 The chance of carcinoma developing from gastric dysplasia may depend on the histological type and grade, size, and surface appearance of the gastric dysplasia.4,5 Therefore, a lesion diagnosed as high-grade dysplasia (HGD; category 4 in the Vienna classification) based on pathological examination of endoscopic forceps biopsy specimens should be considered for endoscopic resection (ER).6,7
In contrast to HGD, however, there is controversy as to what the best treatment option is for low-grade dysplasia (LGD). Some authors have asserted that endoscopic surveillance with re-biopsy should be scheduled periodically because of the low risk of malignant transformation,8,9 whereas others have suggested that the guiding principle for the management of LGD should be ER of the lesion.5,10 If the endoscopic forceps biopsy is representative of the entire lesion, endoscopic follow-up should be sufficient to manage LGD. However, a finding of low-grade dysplasia (category 3 in the Vienna classification) based on forceps biopsy material does not completely exclude the presence of HGD or carcinoma in other parts of the lesion.4,11,12 In particular, even though accurate diagnostic information can be obtained via endoscopic forceps biopsy, the histological discrepancy between endoscopic forceps biopsy specimens and ER has been reported to range from 25% to 40%.13-16 In this study, we investigated the predictive endoscopic features of HGD or early gastric cancer (EGC) of lesions originally diagnosed as LGD based on a forceps biopsy.
From July 2005 to May 2009, 241 patients diagnosed with LGD lesions by initial endoscopic forceps biopsy were retrospectively enrolled and underwent ER at Yonsei University Wonju Christian Hospital, Korea. This study was approved by the local Institutional Review Board, Yonsei University Wonju College of Medicine, Wonju, Korea and all patients were provided written informed consent to participate in the study. After ER, all lesions were assigned to one of two groups based on the final histological findings: an up-graded histology group (UH; LGD to HGD or EGC) or a concordant histology group (CDH; LGD to gastritis or LGD).
ER was performed by endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). Gastric lesions were first identified and demarcated using white-light endoscopy and chromoendoscopy with an indigo-carmine solution (GIF-Q 240, 260; Olympus Optical Co., Ltd., Tokyo, Japan). Marking around the lesions was achieved with spotty cautery using argon plasma coagulation. Isotonic saline mixed with epinephrine (1:10,000) was injected into the submucosal layer to produce a mucosal bleb. A circumferential mucosal incision was made around the lesion and then resection with a snare (EMR or polypectomy) or a hook knife and/or insulated tipped knife (Olympus Optical Co., Ltd.) ESD was performed. All patients were sedated by intravenous injection of 3 to 4 mg of midazolam and/or 20 mg of propofol. Ten to 20 mg of propofol was additionally given for conscious sedation as needed throughout the procedure.
To determine predictive variables for UH, the size, number of forceps biopsy specimens, location of the dysplastic lesion, surface nodularity or redness, presence of a depressed portion,
One expert gastrointestinal pathologist reviewed the histopathological findings of both endoscopic forceps biopsy materials and the endoscopically resected specimen. Biopsy specimens from the gastric lesion were fixed in formalin and bisected for hematoxylin-eosin (H&E) staining. The resected specimens were also fixed on a flat board and observed macroscopically; they were then fixed in formalin and examined in step sections. The resected specimens were sectioned perpendicularly at 2 mm intervals. All of the lesions were classified according to the standardized Vienna classification guidelines for gastrointestinal neoplasia.12
All statistical tests performed were two-sided tests and a p value of less than 0.05 was considered statistically significant. Statistical analyses were performed using the SPSS PC software program (SPSS Inc., Chicago, IL, USA). Associations between the categorical parameters and sub-groups of UH and CDH were assessed by the chi-square test. Multiple logistic regression analyses to determine predictive factors for an upgraded histology after ER were performed to examine the effects of independent variables, and adjustments were made for the effects of each of the variables on the other variables. Medical statistician supported the study design and analysis of data.
A total of 241 patients (mean age, 62.6±10 years; M:F=175:66) were enrolled in this study, for a total of 251 lesions. Among 241 cases, 23 (9.5%) have multiple lesions; 21 cases had double lesions and the rest 2 had triple lesions. All of multiple lesions, the initial biopsies were performed in 10 cases. The mean size of the lesions was 12.8±7.9 mm and the number of forceps biopsies performed per lesion was 2.5±1.3. When we divided the gastric area into three sections (fundus, angle, and antrum), 160 cases were located on the antrum. The frequencies of a depressed portion, surface nodularity, and redness were 46%, 55%, and 39%, respectively. The frequencies of
Among 241 patients diagnosed with LGD on forceps biopsy, 151 cases (60%) showed a concordant histology after ER whereas 100 cases (40%) had a different histology: 39 cases of adenocarcinoma, 56 cases of HGD, and 5 cases of chronic gastritis. Among 39 cases of adenocarcinoma, all except one moderately differentiated cancer were well differentiated tumor. Therefore, 38% (95/251) of lesions initially diagnosed as LGD on forceps biopsy were upgraded after ER (Table 1).
Examples of histological discrepancies are provided in Figs. 1 and 2. Fig. 1 shows a lesion that was upgraded to HGD, whereas Fig. 2 shows a lesion that was upgraded to an adenocarcinoma.
A comparison of the lesion and patient characteristics according to UH or CDH group is provided in Table 2. In 39 of 95 cases (41%) with UH, the lesion size was larger than 15 mm. Of 156 cases with CDH, only 37 cases (23.7%) were larger than 15 mm. Fifty-two of 95 cases (54.7%) with UH had a depressed portion present in the lesion; however, 52 of 156 cases (33.3%) with CDH had a depressed portion in the lesion. Sixty-five of 95 cases (68.4%) with UH had surface nodularity, while 72 of 156 cases (46.2%) with CDH had surface nodularity.
On univariate analysis, a large size, presence of a depressed portion, and surface nodularity were significantly related to UH (Table 2). On multivariate analysis of risk factors of UH, a large size and a depressed lesion were significant risk factors for UH after ER of lesions diagnosed as LGD by forceps biopsy (odds ratios of 2.8 and 2.7, respectively) (Table 3). There were no significant associations between UH and age, sex, surface redness, number of forceps biopsy specimens,
A comparison of the lesion according to non-EGC (early gastric cancer) or EGC group is provided in Table 4. In 21 of 39 cases (53.8%) with EGC, the lesion size was larger than 15 mm. Of 212 cases with non-EGC, only 55 cases (25.9%) were larger than 15 mm. Twenty-eight of 39 cases (71.8%) with EGC had a depressed portion present in the lesion; however, 86 of 212 cases (40.6%) with non-EGC had a depressed portion in the lesion. Twenty-seven of 39 cases (71.8%) with EGC had surface nodularity, while 111 of 212 cases (52.4%) with non-EGC had surface nodularity.
On univariate analysis, a large size, presence of a depressed portion, and surface nodularity were significantly related to EGC (Table 4).
Gastric dysplasia is known to be a precursor lesion of gastric carcinoma and is classified as "noninvasive neoplasia" by the Padova International Classification system.2 Gastric dysplasia can be categorized as low-grade or high-grade based on the severity of histological abnormalities using a two-tier system.12 The characteristics of LGD are multiple small, round, glandular structures similar to adenomatous polyps in the colon. However, it is often difficult to discriminate gastric dysplasia in practice for several reasons. The first reason is interobserver variability. Fertitta et al.8 reported that 51% of cases initially diagnosed as moderate dysplasia by general pathologists were confirmed as hyperplastic or metaplastic lesions. The second reason is specimen size. Because the specimens obtained using forceps biopsy are tiny and often break into splinters, the whole lesion is not represented and the disease severity may be under-diagnosed. A third reason is the pathophysiology of gastric carcinogenesis. A series of changes have been identified as precursors to the intestinal type of gastric carcinoma, representing apparently sequential steps in the precancerous process, namely superficial gastritis, chronic atrophic gastritis, intestinal metaplasia, dysplasia, and cancer.13 Similarly, the genetic evolution of cancer involves the accumulation of multiple mutations. In gastric cancer, altered loci include p53, APC, K-ras, and there is also microsatellite instability in cancers with a replication error (RER) or ubiquitous somatic mutation (USM) phenotype.14 Thus, various degrees of dysplasia can coexist in the same lesion, making the lesion heterogeneous. Despite these limitations, however, endoscopic biopsy results are essential for clinicians to formulate their treatment plan. In this study, we investigated which endoscopic features were risk factors for upgrading a lesion initially diagnosed as LGD based on forceps biopsy. We focused on LGD histology for several important reasons. First, LGD has a histologically vague position. Until very recently, there was a substantial lack of agreement on the issue of dysplasia and its grading among pathologists, especially between those from Japan and Western countries. As a result of two consensus conferences held in Padova and Vienna, we now have the Padova International Classification2 and the Vienna Classification.12 When the pathologists involved in creating the Padova Classification participated in a test of variability after the conference, there was general agreement between them 77.7% to 86.5% of the time.17 The κ coefficients were a little over 0.6, indicating moderately good agreement. However, interobserver variability in diagnosing dysplasia is inevitable whenever a continuous spectrum is subjectively divided. The difficulty in differentiating reactive from dysplastic changes may account for reports of the reversibility of LGD.18 For this reason, interobserver variability could occur more often in LGD cases. In our study, a single expert gastrointestinal pathologist reviewed forceps biopsy materials and resected specimens, thereby ensuring no interobserver variability.
Second, the best treatment option for LGD is unclear. Using the two-tier system of classification, low-grade dysplasia was shown to regress in between 38% and 49% of cases, to persist in 19% to 28%, and to progress to high-grade dysplasia in between 0% and 15% of cases. High-grade dysplasia regressed in about 5% of cases, persisted in 14%, and progressed in 81% to 85%.17,19 For these reasons, a lesion diagnosed as high-grade dysplasia by endoscopic forceps biopsy material should be considered for ER.6,7 Several long-term follow-up studies have demonstrated that LGD lesions do not progress rapidly to HGD or carcinoma, thus some authors have advocated a management approach of scheduled endoscopic surveillance and re-biopsy.9,20 However, other groups have suggested removal of the LGD lesions because of the histological discrepancy between forceps biopsy specimens and resected specimens.21-23 In our study, substantial lesions initially characterized as LGD based on forceps biopsy were up-graded after ER (39%), whereas only 2% of lesions were down-graded. Furthermore, scarring changes in the lesion due to multiple biopsies could interfere with ER. Hull et al.24 reported that EMR is superior to biopsy for the diagnostic evaluation of large lesions. Therefore, endoscopic forceps biopsy findings as well as endoscopic findings known to be related to upgrading of lesions should be considered when planning the management of LGD lesions.
The histological discrepancy between endoscopic biopsy specimens and surgical specimens has been reported to range from 25% to 40%.13-16,25-27 In our study, a histological discrepancy between the forceps biopsy specimens and the ER specimens was confirmed in 100/251 (39.8%) of total cases. We therefore hypothesized that important information could be extracted from the endoscopic findings. Recent studies reported that large lesions (>15 mm), redness, nodularity of surface lesions, and the presence of a depressed portion were markers for malignancy risk.4,5 Furthermore, adenomatous polyps with a diameter greater than 2 cm size have been regarded as having malignant potential.28 In our study, lesions larger than 15 mm, those with a depressed portion, and those with surface nodularity were more often presented in the UH group than the CDH group. In addition, these parameters were more often presented in the EGC group than the non-EGC group based on final pathologic reports (Table 3). In the multivariate analysis, the risk of UH was increased significantly by 2.8-fold in lesions larger than 15 mm and 2.7-fold in lesions with a depressed portion. These results suggest that the size of lesions and the existence of a depressed portion may be risk factors related with UH. In our study 39/251 (15.5%) cases were diagnosed as EGC after ER. According to several studies in Korea, the proportion of cancer patients who were initially diagnosed as LGD but finally diagnosed by resection pathology ranged from 7.8% to 34%,29-33 which was consistent with our data. One explanation for high percentage of EGCs in almost study was that every study included only endoscopically resected cases which were likely to be high risk of cancer. Interestingly, 5 cases (2.1%) were reported as gastritis after ER. With regard to this point, Kim et al.34 reported that 3.2% was found to be negative after ER and this was similar to our result. They suggested several possible reasons for this; small tumors removed by the previous forceps biopsy, sampling error and a different location.
However, our study had some limitations. First, there is the possibility of selection bias because this study was performed retrospectively. Unfortunately, we could not present the exact number of LGD patients who might not be treated due to old age or comorbidity, or treated in another hospital because we searched the cases with key words of LGD and ER in a retrospective manner. Also, we had a difficulty to find the number of LGD diagnosed in our institution during the study period, because our medical records was determined by the final diagnosis of ER, the gold standard of this study. Endoscopic ablation for LGD was performed in only 2 cases. Because we included all cases of endoscopically resection during the study period, the number of LGD cases who may not be included in the study should be small. Therefore, it's very unlikely these cases affect the results of this study. Second, the concordance rate of endoscopic findings between observers was not investigated. Third, the number of forceps biopsies performed per patient differed. Further prospective studies are required to address these limitations.
In conclusion, we suggest that additional ER should be preferentially considered for lesions with a depressed portion or those larger than 15 mm, even if endoscopic biopsy shows LGD.
Gut Liver 2011; 5(2): 187-193
Published online June 30, 2011 https://doi.org/10.5009/gnl.2011.5.2.187
Copyright © Gut and Liver.
Chan Sik Won*, Mee Yon Cho†, Hyun Soo Kim**, Hye Jeong Kim*, Ki Tae Suk‡, Moon Young Kim*, Jae Woo Kim*, Soon Koo Baik*, and Sang Ok Kwon*
*Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
†Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea.
‡Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.
Correspondence to: Hyun Soo Kim. Department of Internal Medicine, Yonsei University Wonju College of Medicine, 162 Ilsan-dong, Wonju 220-701, Korea. Tel: +82-33-741-1229, Fax: +82-33-745-6782, hyskim@yonsei.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gastric dysplasia is generally accepted to be the precursor lesion of gastric carcinoma. Approximately 25% to 35% of histological diagnoses based on endoscopic forcep biopsies for gastric dysplastic lesions change following endoscopic resection (ER). The aim of this study was to determine the predictive endoscopic features of high-grade gastric dysplasia (HGD) or early gastric cancer (EGC) following ER for lesions initially diagnosed as low-grade dysplasia (LGD) by a forceps biopsy.
To determine predictive variables for upgraded histology (LGD to HGD or EGC). The lesion size, gross endoscopic appearance, location, and surface nodularity or redness as well as the presence of a depressed portion,
Among 251 LGDs diagnosed by an initial forceps biopsy, the diagnoses of 100 lesions (39.8%) changed following the ER; 56 of 251 LGDs (22.3%) were diagnosed as HGD, 39 (15.5%) as adenocarcinoma, and 5 (2.0%) as chronic gastritis. In a univariate analysis, large lesions (>15 mm), those with a depressed portion, and those with surface nodularity were significantly correlated with a upgraded histology classification following ER. In a multivariate analysis, a large size (>15 mm; odds ratio [OR], 2.8; 95% confidence interval [CI], 1.46 to 5.43) and a depressed portion in the lesion (OR, 2.7; 95% CI, 1.44 to 5.03) were predictive factors for upgraded histology following ER.
Our study shows that a substantial proportion of diagnoses of low-grade gastric dysplasias based on forceps biopsies were not representative of the entire lesion. We recommend ER for lesions with a depressed portion and for those larger than 15 mm.
Keywords: Gastric dysplasia, Endoscopic forcep biopsy, Endoscopic resection, Early gastric cancer
Dysplasia refers to an unequivocal neoplastic transformation in the epithelium without penetration into the lamina propria (intramucosal carcinoma).1,2 Gastric dysplasia is generally accepted to be a precursor lesion for gastric carcinoma.3 The chance of carcinoma developing from gastric dysplasia may depend on the histological type and grade, size, and surface appearance of the gastric dysplasia.4,5 Therefore, a lesion diagnosed as high-grade dysplasia (HGD; category 4 in the Vienna classification) based on pathological examination of endoscopic forceps biopsy specimens should be considered for endoscopic resection (ER).6,7
In contrast to HGD, however, there is controversy as to what the best treatment option is for low-grade dysplasia (LGD). Some authors have asserted that endoscopic surveillance with re-biopsy should be scheduled periodically because of the low risk of malignant transformation,8,9 whereas others have suggested that the guiding principle for the management of LGD should be ER of the lesion.5,10 If the endoscopic forceps biopsy is representative of the entire lesion, endoscopic follow-up should be sufficient to manage LGD. However, a finding of low-grade dysplasia (category 3 in the Vienna classification) based on forceps biopsy material does not completely exclude the presence of HGD or carcinoma in other parts of the lesion.4,11,12 In particular, even though accurate diagnostic information can be obtained via endoscopic forceps biopsy, the histological discrepancy between endoscopic forceps biopsy specimens and ER has been reported to range from 25% to 40%.13-16 In this study, we investigated the predictive endoscopic features of HGD or early gastric cancer (EGC) of lesions originally diagnosed as LGD based on a forceps biopsy.
From July 2005 to May 2009, 241 patients diagnosed with LGD lesions by initial endoscopic forceps biopsy were retrospectively enrolled and underwent ER at Yonsei University Wonju Christian Hospital, Korea. This study was approved by the local Institutional Review Board, Yonsei University Wonju College of Medicine, Wonju, Korea and all patients were provided written informed consent to participate in the study. After ER, all lesions were assigned to one of two groups based on the final histological findings: an up-graded histology group (UH; LGD to HGD or EGC) or a concordant histology group (CDH; LGD to gastritis or LGD).
ER was performed by endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). Gastric lesions were first identified and demarcated using white-light endoscopy and chromoendoscopy with an indigo-carmine solution (GIF-Q 240, 260; Olympus Optical Co., Ltd., Tokyo, Japan). Marking around the lesions was achieved with spotty cautery using argon plasma coagulation. Isotonic saline mixed with epinephrine (1:10,000) was injected into the submucosal layer to produce a mucosal bleb. A circumferential mucosal incision was made around the lesion and then resection with a snare (EMR or polypectomy) or a hook knife and/or insulated tipped knife (Olympus Optical Co., Ltd.) ESD was performed. All patients were sedated by intravenous injection of 3 to 4 mg of midazolam and/or 20 mg of propofol. Ten to 20 mg of propofol was additionally given for conscious sedation as needed throughout the procedure.
To determine predictive variables for UH, the size, number of forceps biopsy specimens, location of the dysplastic lesion, surface nodularity or redness, presence of a depressed portion,
One expert gastrointestinal pathologist reviewed the histopathological findings of both endoscopic forceps biopsy materials and the endoscopically resected specimen. Biopsy specimens from the gastric lesion were fixed in formalin and bisected for hematoxylin-eosin (H&E) staining. The resected specimens were also fixed on a flat board and observed macroscopically; they were then fixed in formalin and examined in step sections. The resected specimens were sectioned perpendicularly at 2 mm intervals. All of the lesions were classified according to the standardized Vienna classification guidelines for gastrointestinal neoplasia.12
All statistical tests performed were two-sided tests and a p value of less than 0.05 was considered statistically significant. Statistical analyses were performed using the SPSS PC software program (SPSS Inc., Chicago, IL, USA). Associations between the categorical parameters and sub-groups of UH and CDH were assessed by the chi-square test. Multiple logistic regression analyses to determine predictive factors for an upgraded histology after ER were performed to examine the effects of independent variables, and adjustments were made for the effects of each of the variables on the other variables. Medical statistician supported the study design and analysis of data.
A total of 241 patients (mean age, 62.6±10 years; M:F=175:66) were enrolled in this study, for a total of 251 lesions. Among 241 cases, 23 (9.5%) have multiple lesions; 21 cases had double lesions and the rest 2 had triple lesions. All of multiple lesions, the initial biopsies were performed in 10 cases. The mean size of the lesions was 12.8±7.9 mm and the number of forceps biopsies performed per lesion was 2.5±1.3. When we divided the gastric area into three sections (fundus, angle, and antrum), 160 cases were located on the antrum. The frequencies of a depressed portion, surface nodularity, and redness were 46%, 55%, and 39%, respectively. The frequencies of
Among 241 patients diagnosed with LGD on forceps biopsy, 151 cases (60%) showed a concordant histology after ER whereas 100 cases (40%) had a different histology: 39 cases of adenocarcinoma, 56 cases of HGD, and 5 cases of chronic gastritis. Among 39 cases of adenocarcinoma, all except one moderately differentiated cancer were well differentiated tumor. Therefore, 38% (95/251) of lesions initially diagnosed as LGD on forceps biopsy were upgraded after ER (Table 1).
Examples of histological discrepancies are provided in Figs. 1 and 2. Fig. 1 shows a lesion that was upgraded to HGD, whereas Fig. 2 shows a lesion that was upgraded to an adenocarcinoma.
A comparison of the lesion and patient characteristics according to UH or CDH group is provided in Table 2. In 39 of 95 cases (41%) with UH, the lesion size was larger than 15 mm. Of 156 cases with CDH, only 37 cases (23.7%) were larger than 15 mm. Fifty-two of 95 cases (54.7%) with UH had a depressed portion present in the lesion; however, 52 of 156 cases (33.3%) with CDH had a depressed portion in the lesion. Sixty-five of 95 cases (68.4%) with UH had surface nodularity, while 72 of 156 cases (46.2%) with CDH had surface nodularity.
On univariate analysis, a large size, presence of a depressed portion, and surface nodularity were significantly related to UH (Table 2). On multivariate analysis of risk factors of UH, a large size and a depressed lesion were significant risk factors for UH after ER of lesions diagnosed as LGD by forceps biopsy (odds ratios of 2.8 and 2.7, respectively) (Table 3). There were no significant associations between UH and age, sex, surface redness, number of forceps biopsy specimens,
A comparison of the lesion according to non-EGC (early gastric cancer) or EGC group is provided in Table 4. In 21 of 39 cases (53.8%) with EGC, the lesion size was larger than 15 mm. Of 212 cases with non-EGC, only 55 cases (25.9%) were larger than 15 mm. Twenty-eight of 39 cases (71.8%) with EGC had a depressed portion present in the lesion; however, 86 of 212 cases (40.6%) with non-EGC had a depressed portion in the lesion. Twenty-seven of 39 cases (71.8%) with EGC had surface nodularity, while 111 of 212 cases (52.4%) with non-EGC had surface nodularity.
On univariate analysis, a large size, presence of a depressed portion, and surface nodularity were significantly related to EGC (Table 4).
Gastric dysplasia is known to be a precursor lesion of gastric carcinoma and is classified as "noninvasive neoplasia" by the Padova International Classification system.2 Gastric dysplasia can be categorized as low-grade or high-grade based on the severity of histological abnormalities using a two-tier system.12 The characteristics of LGD are multiple small, round, glandular structures similar to adenomatous polyps in the colon. However, it is often difficult to discriminate gastric dysplasia in practice for several reasons. The first reason is interobserver variability. Fertitta et al.8 reported that 51% of cases initially diagnosed as moderate dysplasia by general pathologists were confirmed as hyperplastic or metaplastic lesions. The second reason is specimen size. Because the specimens obtained using forceps biopsy are tiny and often break into splinters, the whole lesion is not represented and the disease severity may be under-diagnosed. A third reason is the pathophysiology of gastric carcinogenesis. A series of changes have been identified as precursors to the intestinal type of gastric carcinoma, representing apparently sequential steps in the precancerous process, namely superficial gastritis, chronic atrophic gastritis, intestinal metaplasia, dysplasia, and cancer.13 Similarly, the genetic evolution of cancer involves the accumulation of multiple mutations. In gastric cancer, altered loci include p53, APC, K-ras, and there is also microsatellite instability in cancers with a replication error (RER) or ubiquitous somatic mutation (USM) phenotype.14 Thus, various degrees of dysplasia can coexist in the same lesion, making the lesion heterogeneous. Despite these limitations, however, endoscopic biopsy results are essential for clinicians to formulate their treatment plan. In this study, we investigated which endoscopic features were risk factors for upgrading a lesion initially diagnosed as LGD based on forceps biopsy. We focused on LGD histology for several important reasons. First, LGD has a histologically vague position. Until very recently, there was a substantial lack of agreement on the issue of dysplasia and its grading among pathologists, especially between those from Japan and Western countries. As a result of two consensus conferences held in Padova and Vienna, we now have the Padova International Classification2 and the Vienna Classification.12 When the pathologists involved in creating the Padova Classification participated in a test of variability after the conference, there was general agreement between them 77.7% to 86.5% of the time.17 The κ coefficients were a little over 0.6, indicating moderately good agreement. However, interobserver variability in diagnosing dysplasia is inevitable whenever a continuous spectrum is subjectively divided. The difficulty in differentiating reactive from dysplastic changes may account for reports of the reversibility of LGD.18 For this reason, interobserver variability could occur more often in LGD cases. In our study, a single expert gastrointestinal pathologist reviewed forceps biopsy materials and resected specimens, thereby ensuring no interobserver variability.
Second, the best treatment option for LGD is unclear. Using the two-tier system of classification, low-grade dysplasia was shown to regress in between 38% and 49% of cases, to persist in 19% to 28%, and to progress to high-grade dysplasia in between 0% and 15% of cases. High-grade dysplasia regressed in about 5% of cases, persisted in 14%, and progressed in 81% to 85%.17,19 For these reasons, a lesion diagnosed as high-grade dysplasia by endoscopic forceps biopsy material should be considered for ER.6,7 Several long-term follow-up studies have demonstrated that LGD lesions do not progress rapidly to HGD or carcinoma, thus some authors have advocated a management approach of scheduled endoscopic surveillance and re-biopsy.9,20 However, other groups have suggested removal of the LGD lesions because of the histological discrepancy between forceps biopsy specimens and resected specimens.21-23 In our study, substantial lesions initially characterized as LGD based on forceps biopsy were up-graded after ER (39%), whereas only 2% of lesions were down-graded. Furthermore, scarring changes in the lesion due to multiple biopsies could interfere with ER. Hull et al.24 reported that EMR is superior to biopsy for the diagnostic evaluation of large lesions. Therefore, endoscopic forceps biopsy findings as well as endoscopic findings known to be related to upgrading of lesions should be considered when planning the management of LGD lesions.
The histological discrepancy between endoscopic biopsy specimens and surgical specimens has been reported to range from 25% to 40%.13-16,25-27 In our study, a histological discrepancy between the forceps biopsy specimens and the ER specimens was confirmed in 100/251 (39.8%) of total cases. We therefore hypothesized that important information could be extracted from the endoscopic findings. Recent studies reported that large lesions (>15 mm), redness, nodularity of surface lesions, and the presence of a depressed portion were markers for malignancy risk.4,5 Furthermore, adenomatous polyps with a diameter greater than 2 cm size have been regarded as having malignant potential.28 In our study, lesions larger than 15 mm, those with a depressed portion, and those with surface nodularity were more often presented in the UH group than the CDH group. In addition, these parameters were more often presented in the EGC group than the non-EGC group based on final pathologic reports (Table 3). In the multivariate analysis, the risk of UH was increased significantly by 2.8-fold in lesions larger than 15 mm and 2.7-fold in lesions with a depressed portion. These results suggest that the size of lesions and the existence of a depressed portion may be risk factors related with UH. In our study 39/251 (15.5%) cases were diagnosed as EGC after ER. According to several studies in Korea, the proportion of cancer patients who were initially diagnosed as LGD but finally diagnosed by resection pathology ranged from 7.8% to 34%,29-33 which was consistent with our data. One explanation for high percentage of EGCs in almost study was that every study included only endoscopically resected cases which were likely to be high risk of cancer. Interestingly, 5 cases (2.1%) were reported as gastritis after ER. With regard to this point, Kim et al.34 reported that 3.2% was found to be negative after ER and this was similar to our result. They suggested several possible reasons for this; small tumors removed by the previous forceps biopsy, sampling error and a different location.
However, our study had some limitations. First, there is the possibility of selection bias because this study was performed retrospectively. Unfortunately, we could not present the exact number of LGD patients who might not be treated due to old age or comorbidity, or treated in another hospital because we searched the cases with key words of LGD and ER in a retrospective manner. Also, we had a difficulty to find the number of LGD diagnosed in our institution during the study period, because our medical records was determined by the final diagnosis of ER, the gold standard of this study. Endoscopic ablation for LGD was performed in only 2 cases. Because we included all cases of endoscopically resection during the study period, the number of LGD cases who may not be included in the study should be small. Therefore, it's very unlikely these cases affect the results of this study. Second, the concordance rate of endoscopic findings between observers was not investigated. Third, the number of forceps biopsies performed per patient differed. Further prospective studies are required to address these limitations.
In conclusion, we suggest that additional ER should be preferentially considered for lesions with a depressed portion or those larger than 15 mm, even if endoscopic biopsy shows LGD.
Table 1 Histological Comparison of Forceps Biopsy Specimens and Resected Specimens
LGD, low-grade dysplasia; HGD, high-grade dysplasia; CIS, carcinoma
Table 2 Comparison between UH and CDH Groups Following Endoscopic Resection
UH, upgraded histology; CDH, concordant or down-graded histology; NS, not significant.
Table 3 Multivariate Analysis of Risk Factors for UH Following Endoscopic Resection
UH, upgraded histology; OR, odds ratio; CI, confidence interval.
Table 4 Comparison of Non-EGCs and EGCs Following Endoscopic Resection
EGC, early gastric cancer; NS, not significant.